Longeveron Inc. Common Stock (LGVN) Stock Price

LGVNStock

$1.39−83.21%52W

Market Cap$4.43M

P/E—

PEG Ratio—

Div yield—

Beta0.89

LGVN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-97.49%

Price vs S&P 500 (4W)-41.94%

VGM Score12.87

Book Value / Share (Quarterly)$2.32

P/TBV (Annual)3.18x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-0.63%

Cash Flow / Share (Quarterly)$-4.62

Price vs S&P 500 (YTD)-84.46%

Gross Margin (TTM)69.76%

Net Profit Margin (TTM)-1977.59%

EPS (TTM)$-6.72

10-Day Avg Trading Volume0.08M

EPS Excl Extra (TTM)$-6.72

Revenue Growth (5Y)-26.60%

EPS (Annual)$-12.92

ROI (Annual)-400.07%

Gross Margin (Annual)66.97%

Net Profit Margin (5Y Avg)-1685.60%

Cash / Share (Quarterly)$2.25

Revenue Growth QoQ (YoY)-9.18%

ROA (Last FY)-221.26%

Revenue Growth TTM (YoY)-42.74%

EBITD / Share (TTM)$-3.46

ROE (5Y Avg)-185.61%

Operating Margin (TTM)-1992.84%

Cash Flow / Share (Annual)$-5.30

P/B Ratio0.43x

P/B Ratio (Quarterly)2.14x

Net Income / Employee (Annual)$-873,200

EV / Revenue (TTM)-4.76x

Net Interest Coverage (TTM)-4260.25x

ROA (TTM)-150.20%

EPS Incl Extra (Annual)$-12.92

Current Ratio (Annual)1.33x

Quick Ratio (Quarterly)2.35x

3-Month Avg Trading Volume0.08M

52-Week Price Return-83.21%

Revenue / Employee (TTM)$45,700

Tangible BV / Share (Quarterly)$1.83

P/S Ratio (Annual)3.70x

Asset Turnover (Annual)0.12x

52-Week High$12.30

Operating Margin (5Y Avg)-1686.28%

EPS Excl Extra (Annual)$-12.92

CapEx CAGR (5Y)17.87%

26-Week Price Return-87.59%

Quick Ratio (Annual)1.17x

13-Week Price Return-77.65%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)2.63x

Enterprise Value$-5.65M

Revenue / Share Growth (5Y)-25.68%

Asset Turnover (TTM)0.08x

Revenue / Employee (Annual)$46,100

Pretax Margin (Annual)-1893.58%

Cash / Share (Annual)$1.28

3-Month Return Std Dev152.02%

Gross Margin (5Y Avg)52.55%

Net Income / Employee (TTM)$-902,800

ROE (Last FY)-400.07%

Net Interest Coverage (Annual)-73.31x

EPS Basic Excl Extra (Annual)$-12.92

Receivables Turnover (TTM)24.73x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-6.72

Receivables Turnover (Annual)12.76x

ROI (TTM)-223.19%

P/S Ratio (TTM)3.73x

Pretax Margin (5Y Avg)-1685.60%

Revenue / Share (Annual)$0.68

Tangible BV / Share (Annual)$0.93

Price vs S&P 500 (52W)-98.74%

Year-to-Date Return-72.53%

5-Day Price Return-43.27%

EPS Normalized (Annual)$-12.92

ROA (5Y Avg)-113.92%

Net Profit Margin (Annual)-1893.58%

Month-to-Date Return-48.33%

Cash Flow / Share (TTM)$-0.89

EBITD / Share (Annual)$-12.55

Operating Margin (Annual)-1942.20%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-185.61%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-6.72

P/TBV (Quarterly)2.71x

P/B Ratio (Annual)1.90x

Pretax Margin (TTM)-1977.59%

Book Value / Share (Annual)$1.56

Price vs S&P 500 (13W)-80.34%

Beta0.89x

Revenue / Share (TTM)$0.38

ROE (TTM)-223.19%

52-Week Low$1.36

gGradeF

mGradeF

vgmGradeF

LGVN Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 12, 2026	-$1.90	-$1.90	+0.00%(+$0.00)
Q1 2026	May 13, 2026	-$1.73	-$1.90	-10.14%(-$0.17)
Q4 2025	Mar 17, 2026	-$3.67	-$2.20	+40.00%(+$1.47)
Q3 2025	Nov 4, 2025	-$2.57	-$3.90	-51.95%(-$1.33)
Q2 2025	Aug 13, 2025	-$0.35	-$0.33	+6.38%(+$0.02)

LGVN Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.00

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
LGVNLongeveron Inc. Common Stock	—	F	F	3.7x	-42.7%	69.8%	—	$1.39
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Longeveron Inc. Common Stock

Longeveron Inc is a clinical-stage biotechnology company developing Lomecel-B, an allogeneic stem cell therapy designed to promote tissue repair and regeneration in aging-related and life-threatening diseases. The company is advancing three pipeline programs targeting Hypoplastic Left Heart Syndrome, Alzheimer's disease, and aging-related frailty.